Pharmacy Services
Rosuvastatin (Crestor) - Myopathy and Rhabdomyolysis in Asian-Americans at 40 mg Dose
February 22, 2005
Patients treated with tiagabine (Gabatril) for off-label uses such as psychiatric illness have an increased risk of seizures. More than 30 patients without epilepsy have experienced seizures during tiagabine therapy. Prescribers are strongly urged to stop off-label use of tiagabine due to this increased risk of seizures.
The FDA has issued a MedWatch safety alert and Cephalon has updated the product labeling with this information. Additional information is available online at the following links:
- MedWatch Alert:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm151502.htm - Dear Healthcare Professional letter:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164622.htm - Public Health Advisory:
http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051764.htm - Revised product labeling:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020646s014lbl.pdf
Updated
February 22, 2005; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT
Social Media
Copyright © 2013 University of Utah Health Care